Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 950Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Gleevec

02 9Gleevec/Glivec

PharmaCompass

01

Brand Name : Gleevec/Glivec

Imatinib

arrow
CPhI India 2024
Not Confirmed

Brand Name : Gleevec/Glivec

arrow
CPhI India 2024
Not Confirmed

Imatinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 1,188

2019 Revenue in Millions : 1,263

Growth (%) : -6

blank

02

Brand Name : Gleevec/Glivec

Imatinib

arrow
CPhI India 2024
Not Confirmed

Brand Name : Gleevec/Glivec

arrow
CPhI India 2024
Not Confirmed

Imatinib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 1,024

2020 Revenue in Millions : 1,188

Growth (%) : -14

blank

03

Brand Name : Gleevec/Glivec

Imatinib

arrow
CPhI India 2024
Not Confirmed

Brand Name : Gleevec/Glivec

arrow
CPhI India 2024
Not Confirmed

Imatinib

Main Therapeutic Indication : Hematology

Currency : USD

2022 Revenue in Millions : 745

2021 Revenue in Millions : 1,024

Growth (%) : -27

blank

04

Brand Name : Gleevec/Glivec

Imatinib Mesylate

arrow
CPhI India 2024
Not Confirmed

Brand Name : Gleevec/Glivec

arrow
CPhI India 2024
Not Confirmed

Imatinib Mesylate

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 561

2022 Revenue in Millions : 745

Growth (%) : -25

blank

05

Brand Name : Gleevec

Imatinib Mesylate

arrow
CPhI India 2024
Not Confirmed

06

Brand Name : Gleevec/Glivec

Imatinib Mesylate

arrow
CPhI India 2024
Not Confirmed

Brand Name : Gleevec/Glivec

arrow
CPhI India 2024
Not Confirmed

Imatinib Mesylate

Main Therapeutic Indication : Oncology

Currency : USD

2015 Revenue in Millions : 4,746

2014 Revenue in Millions : 4,658

Growth (%) : -2%

blank

07

Brand Name : Gleevec/Glivec

Imatinib Mesylate

arrow
CPhI India 2024
Not Confirmed

Brand Name : Gleevec/Glivec

arrow
CPhI India 2024
Not Confirmed

Imatinib Mesylate

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 3,323

2015 Revenue in Millions : 4,658

Growth (%) : -29

blank

08

Brand Name : Gleevec/Glivec

Imatinib Mesylate

arrow
CPhI India 2024
Not Confirmed

Brand Name : Gleevec/Glivec

arrow
CPhI India 2024
Not Confirmed

Imatinib Mesylate

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 1,943

2016 Revenue in Millions : 3,323

Growth (%) : -42

blank

09

Brand Name : Gleevec/Glivec

Imatinib Mesylate

arrow
CPhI India 2024
Not Confirmed

Brand Name : Gleevec/Glivec

arrow
CPhI India 2024
Not Confirmed

Imatinib Mesylate

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 1,561

2017 Revenue in Millions : 1,943

Growth (%) : -20%

blank

10

Brand Name : Gleevec/Glivec

Imatinib

arrow
CPhI India 2024
Not Confirmed

Brand Name : Gleevec/Glivec

arrow
CPhI India 2024
Not Confirmed

Imatinib

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 1,263

2018 Revenue in Millions : 1,561

Growth (%) : -19

blank